Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HER2 SADA

Next Previous
Drug Profile

HER2 SADA

Alternative Names: HER2-SADA

Latest Information Update: 28 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Massachusetts Institute of Technology; Memorial Sloan-Kettering Cancer Center
  • Developer Y-mAbs Therapeutics
  • Class Antibodies; Antineoplastics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Breast cancer

Most Recent Events

  • 28 Mar 2026 No recent reports of development identified for preclinical development in Breast-cancer in USA (IV, Infusion)
  • 19 Mar 2024 Preclinical development is ongoing USA (IV) (Y-mAbs Therapeutics pipeline, March 2024)
  • 31 May 2021 Memorial Sloan Kettering Cancer Center has pending patent applications in Australia, Canada, Brazil, China, Hong Kong, Japan, Eurasia, Europe, India, South Korea, New Zealand and in USA for herceptin conjugated for pre-targeted radioimmunotherapy and application as a theranostic product

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top